Fonte: Science and public policy. Unidade: FM
Assuntos: ANTICORPOS MONOCLONAIS, TERAPÊUTICA, PAÍSES DESENVOLVIDOS, BRASIL
ABNT
SILVA, Renan Gonçalves Leonel da et al. The industry of therapeutic monoclonal antibodies in Brazil: Public policies as instruments of technology upgrading. Science and public policy, v. 50, n. 1, p. 42-58, 2023Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/53044. Acesso em: 19 abr. 2024.APA
Silva, R. G. L. da, Fischer, B. B., Schaeffer, P. R., & Novaes, H. M. D. (2023). The industry of therapeutic monoclonal antibodies in Brazil: Public policies as instruments of technology upgrading. Science and public policy, 50( 1), 42-58. doi:10.1093/scipol/scac047NLM
Silva RGL da, Fischer BB, Schaeffer PR, Novaes HMD. The industry of therapeutic monoclonal antibodies in Brazil: Public policies as instruments of technology upgrading [Internet]. Science and public policy. 2023 ; 50( 1): 42-58.[citado 2024 abr. 19 ] Available from: https://observatorio.fm.usp.br/handle/OPI/53044Vancouver
Silva RGL da, Fischer BB, Schaeffer PR, Novaes HMD. The industry of therapeutic monoclonal antibodies in Brazil: Public policies as instruments of technology upgrading [Internet]. Science and public policy. 2023 ; 50( 1): 42-58.[citado 2024 abr. 19 ] Available from: https://observatorio.fm.usp.br/handle/OPI/53044